



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
✓ 10/623,888	✓ 07/17/2003	1615	✓ 750	✓ 4-20437D	✓	11	✓ 1

CONFIRMATION NO. 7666

001095
 THOMAS HOXIE
 NOVARTIS, CORPORATE INTELLECTUAL PROPERTY
 ONE HEALTH PLAZA 430/2
 EAST HANOVER, NJ 07936-1080



FILING RECEIPT



OC000000011081746

GL

Date Mailed: 10/23/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Robert Gurny, Geneva, SWAZILAND;
 Eric Olivier Allemann, Croix-de-Rozon, SWAZILAND;
 Jean-Christophe Leroux, Geneva, SWAZILAND;

SWITZERLAND



✓ Domestic Priority data as claimed by applicant

This application is a CON of 09/458,622 12/10/1999 ABN
 which is a CON of 09/287,421 04/07/1999 ABN
 which is a CON of 08/945,587 11/20/1997 ABN
 which is a 371 of PCT/EP96/01769 04/26/1996

✓ Foreign Applications

EUROPEAN PATENT OFFICE (EPO) 95810306.1 05/08/1995

If Required, Foreign Filing License Granted: 10/22/2003

Projected Publication Date: 01/29/2004

Non-Publication Request: No


Early Publication Request: No

Title

Nanoparticles for oral administration of pharmaceutical agents of low solubility

Preliminary Class

424



**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

11-24-03

CASE 4-20437D



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL987587343US
Express Mail Label Number

11/21/03
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF Art Unit: 1615

GURNY ET AL.

APPLICATION NO: 10/623,888

FILED: JULY 17, 2003

FOR: NANOPARTICLES FOR ORAL ADMINISTRATION OF
PHARMACEUTICAL AGENTS OF LOW SOLUBILITY

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

LETTER CORRECTING OFFICIAL FILING RECEIPT

Sir:

The official filing receipt received in the above-identified application erroneously lists Applicant(s).

Please issue a corrected filing receipt listing the Applicant(s) as follows:

-- Robert Gurny, Geneva, Switzerland
Eric Olivier Allemand, Croix-de-Rozon, Switzerland
Jean-Christophe Leroux, Geneva, Switzerland --

A copy of the filing receipt with the correction noted is enclosed.

Applicants believe this error is ascribable to the Patent Office. Accordingly, no fees are required.

Respectfully submitted,



Gabriel Lopez
Attorney for Applicants
Reg. No. 28,440
(862) 778-7882

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080

Date: 11/21/03